Literature DB >> 6738565

DNA-ligase activities appear normal in the CHO mutant EM9.

J Y Chan, L H Thompson, F F Becker.   

Abstract

The Chinese hamster ovary (CHO) mutant strain EM9 was previously shown to be hypersensitive to killing by ethyl methanesulfonate (EMS) and methyl methanesulfonate (MMS), to have a 12-fold increased baseline incidence of sister-chromatid exchanges (SCE), and to be defective in rejoining DNA strand breaks after treatment with EMS, MMS, or X-rays. A study was performed to determine if the primary biochemical defect might be a DNA ligase. DNA-ligase activities were assayed and compared after separation of the multiple forms of ligase by AcA 34 gel-filtration chromatography of total cellular extracts. In EM9 cells the levels of the presumptive replicative forms, DNA ligase Ia (480 kd) and ligase Ib (240 kd) were about 50% and 60%, respectively, of those in the parental AA8 cells, whereas DNA ligase II (80 kd) was unaltered in EM9 . In a phenotypic revertant line ( 9R1 ) ligases Ia, Ib and II levels were 35%, 37% and 100%, respectively, of those in AA8 . The reduced levels of ligases Ia and Ib in EM9 and 9R1 cells are apparently not related directly to the mutant phenotype and may be attributable to the somewhat slower growth rates of these strains compared with those of AA8 . To determine if the repair defect in EM9 might reside in the ability to induce DNA-ligase activity after treatment with a DNA-damaging agent, AA8 and EM9 cells were treated with MMS at 30 micrograms/ml for 60 min before preparing fractions for ligase assays. Under these conditions the activities of ligases Ia and Ib decreases 70-80% in both cell lines, but ligase II increased 2.0- and 2.6-fold, respectively, in AA8 and EM9 . As a further test of defective ligase activities in EM9 , assays were performed in the presence of 0.1 M NaCl or after heating the fractions for 10 min at 50 degrees C. Although all 3 forms of ligase showed altered activity under both of these conditions, there were no significant differences between EM9 and AA8 cells. These data combined with the above results provide strong evidence that the site of the primary defect in EM9 is not in either of the DNA ligases .

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6738565     DOI: 10.1016/0167-8817(84)90027-0

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  7 in total

1.  Multiple components are involved in the efficient joining of double stranded DNA breaks in human cell extracts.

Authors:  M P Fairman; A P Johnson; J Thacker
Journal:  Nucleic Acids Res       Date:  1992-08-25       Impact factor: 16.971

2.  Identification of a specific inhibitor for DNA ligase I in human cells.

Authors:  S W Yang; F F Becker; J Y Chan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

3.  Recombination and ligation of transfected DNA in CHO mutant EM9, which has high levels of sister chromatid exchange.

Authors:  C A Hoy; J C Fuscoe; L H Thompson
Journal:  Mol Cell Biol       Date:  1987-05       Impact factor: 4.272

4.  DNA-mediated transfer of a human DNA repair gene that controls sister chromatid exchange.

Authors:  L H Thompson; K W Brookman; J L Minkler; J C Fuscoe; K A Henning; A V Carrano
Journal:  Mol Cell Biol       Date:  1985-04       Impact factor: 4.272

5.  An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III.

Authors:  K W Caldecott; C K McKeown; J D Tucker; S Ljungquist; L H Thompson
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

6.  Characterization of a baculovirus-encoded ATP-dependent DNA ligase.

Authors:  M N Pearson; G F Rohrmann
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

7.  Mammalian DNA ligase III: molecular cloning, chromosomal localization, and expression in spermatocytes undergoing meiotic recombination.

Authors:  J Chen; A E Tomkinson; W Ramos; Z B Mackey; S Danehower; C A Walter; R A Schultz; J M Besterman; I Husain
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.